Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.

about

Effects of vascular formation during alveolar bone process morphogenesis in mice.

P2860

Q38726751-D7A90490-4942-45A2-9884-E60EEF17A75C

P2860

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.

Item

http://www.wikidata.org/entity/Q37070754

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of anti-vascular endot ...... mab) on lens epithelial cells.

@en

Effects of anti-vascular endothelial growth factor monoclonal antibody

@nl

type

Item

label

Effects of anti-vascular endot ...... mab) on lens epithelial cells.

@en

Effects of anti-vascular endothelial growth factor monoclonal antibody

@nl

prefLabel

Effects of anti-vascular endot ...... mab) on lens epithelial cells.

@en

Effects of anti-vascular endothelial growth factor monoclonal antibody

@nl

P1476

Effects of anti-vascular endot ...... mab) on lens epithelial cells.

@en

P2093

Jae-Young Kim

http://www.w3.org/2001/XMLSchema#string

Jong Hwa Jun

http://www.w3.org/2001/XMLSchema#string

Wern-Joo Sohn

http://www.w3.org/2001/XMLSchema#string

Youngkyun Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.

Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival

Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells.

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease

Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia.

Posterior capsule opacification-like changes in rat lens explants cultured with TGFbeta and FGF: effects of cell coverage and regional differences.

Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation.

P304

1167-1174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S103443

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27418802

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

bevacizumab

P932

4935105

http://www.w3.org/2001/XMLSchema#string

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.

about

P2860

P2860

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932